Two Colour Photoflow Chemistry for Macromolecular Design.

We report a photochemical flow setup that exploits λ-orthogonal reactions using two different colours of light (λ1 =350 nm and λ2 =410 nm) in sequential on-line irradiation steps. Critically, both photochemically reactive units (a visible-light reactive chalcone and a UV-activated photo-caged diene) are present in the reaction mixture. We demonstrate the power of two colour photoflow by the wavelength-selective end group modification of photo-caged polymer end groups and the subsequent polymer ring closure driven by a [2+2] cycloaddition. Importantly, we evidence that the high energy gate does not induce the visible light reaction of the chalcone, which attests the true λ-orthogonal nature of the flow reaction system. For the first time, this study opens the realm of photoflow reactions to λ-orthogonal photochemistry.

Targeted and modular architectural polymers employing bioorthogonal chemistry for quantitative therapeutic delivery.

There remain several key challenges to existing therapeutic systems for cancer therapy, such as quantitatively determining the true, tissue-specific drug release profile in vivo, as well as reducing side-effects for an increased standard of care. Hence, it is crucial to engineer new materials that allow for a better understanding of the in vivo pharmacokinetic/pharmacodynamic behaviours of therapeutics. We have expanded on recent "click-to-release" bioorthogonal pro-drug activation of antibody-drug conjugates (ADCs) to develop a modular and controlled theranostic system for quantitatively assessing site-specific drug activation and deposition from a nanocarrier molecule, by employing defined chemistries. The exploitation of quantitative imaging using positron emission tomography (PET) together with pre-targeted bioorthogonal chemistries in our system provided an effective means to assess in real-time the exact amount of active drug administered at precise sites in the animal; our methodology introduces flexibility in both the targeting and therapeutic components that is specific to nanomedicines and offers unique advantages over other technologies. In this approach, the in vivo click reaction facilitates pro-drug activation as well as provides a quantitative means to investigate the dynamic behaviour of the therapeutic agent.